PWZ-029

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
PWZ-029
PWZ-029.svg
Systematic (IUPAC) name
8-chloro-3-(methoxymethyl)-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
Identifiers
PubChem CID: 9971547
ChEMBL CHEMBL45346 N
Chemical data
Formula C14H14ClN3O2
Molecular mass 291.732 g/mol
  • ClC1=CC=C2C(C(N(CC3=C(COC)N=CN32)C)=O)=C1
 NYesY (what is this?)  (verify)

PWZ-029 is a benzodiazepine derivative drug with nootropic effects developed by WiSys,[1] It acts as a subtype-selective, mixed agonist-inverse agonist at the benzodiazepine binding site on the GABAA receptor, acting as a partial inverse agonist at the α5 subtype and a weak partial agonist at the α3 subtype. This gives it a mixed pharmacological profile, producing at low doses memory-enhancing effects but with no convulsant or anxiogenic effects or muscle weakness, although at higher doses it produces some sedative effects.[2]

See also

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
  1. ↑ US Patent application US2006/258643 A1
  2. ↑ Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, Huck S, Sieghart W, Cook JM. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats. Brain Research. 2008 May 7;1208:150-9. doi:10.1016/j.brainres.2008.02.020 PMID 18394590
Retrieved from "https://infogalactic.com/w/index.php?title=PWZ-029&oldid=693472038"